ClinicalTrials.gg
CompletedNCT00821821Updated Jul 16, 2026Results posted

Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke

A Phase 2 interventional study of MCI-186 and Placebo in Acute Ischemic Stroke (AIS), sponsored by Shionogi. Completed at 3 sites in 3 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Shionogi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Ischemic Stroke with a site in Finland — 6 open to participants now, 10 under way, 1 of them phase 3. Ischemic Stroke · Finland.

Enrollment
27th of 30
36 · median 495
Started
2009
with 3 others
Phase 2
7 of 38
none open now
Registered
5th of 38
by date
Lead sponsor
2 of 38
Shionogi

Among the 38 studies in Ischemic Stroke with a site in Finland, this one is the 27th largest by enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2009, is one of 7 in phase 2, and was the 5th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

6 of the 38 studies in Ischemic Stroke with a site in Finland are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Ischemic Stroke with a site in Finland, or all of them as a file.
02

Study summary

The objectives of this study are to assess the safety, tolerability and local tolerance, and to investigate the plasma levels and terminal elimination half life of MCI-186, and to review the routine clinical and neurological assessments data of MCI-186 in subjects with acute ischemic stroke.

03

Conditions studied

  • Acute Ischemic Stroke (AIS)

Browse trials for

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Full functional independence prior to the present stroke (as evidenced by a pre-morbid modified Rankin Scale score of 0-2
  • Clinical diagnosis of acute stroke with CT scan ruling out intracranial hemorrhage
  • Onset of symptoms within 1-24 hours of commencement of infusion of study drug
  • Measurable deficit on NIHSS (as evidenced by a score of 3-15)
  • Full consciousness (i.e. the score for NIHSS item 1a=0)
  • Written valid is obtained from the subject or his/her next of kin or legal representative if the subject is fully conscious (i.e. the score for NIHSS item 1a = 0) but unable to read and/or sign the ICF, in accordance with National legislation and local IRB requirements

Exclusion criteria

Exclusion Criteria:

  • Subjects who are unlikely to complete the infusion of product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition
  • Subjects with severe illness with less than 6 months
  • Body weight in excess of 120 kg
  • Subjects who have received rTPA or other thrombolytics (e.g. urokinase, streptokinase, reteplase, tenecteplase) within the previous 24 hours
  • Likelihood of forbidden concomitant therapy such as vascular surgery, coronary artery bypass graft (CABG), valve replacement, or carotid endarterectomy (CEA)
  • Evidence of cerebral herniation
  • Subjects with confounding neurological diseases such as dementia
  • Subjects with CADASIL, Moya Moya, or carotid dissection
  • Subjects who have experienced a stroke within the previous 3 months (Note: subjects who have recently experienced a , but whose premorbid mRS prior to their stroke is 0-2, will be allowed to enter the study)
  • Evidence from admission imaging tests of infarction involving >1/3 of MCA territory, or entire ACA territory involvement, or internal carotid artery (ICA) occlusions without coexisting separate occlusion of the middle cerebral artery (because of the difficulty distinguishing between chronic and acute ICA lesions in such subjects)
  • Pathology other than cerebral infarction on any admission imaging tests (e.g. ICH or SAH, AV malformation, cerebral aneurysm, or cerebral neoplasm)
  • Current or previous known excessive alcohol use or dependence
  • Current known illicit drug use or dependence
  • Participation in a previous clinical study within 30 days
  • Subjects unlikely to be able and willing to attend all study follow-up visits
  • Any other conditions which in the opinion of the investigator deem the subject ineligible for inclusion
  • Females who are pregnant or intend to become pregnant or subjects (male and female) who do not agree to use effective for 3 months after end of treatment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    MCI-186

    Drug: MCI-186

  • Placebo comparator
    Placebo Group

    Drug: Placebo

Interventions

  • Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion

    Also known as: Edaravone

  • DrugPlacebo

    Cohort1:circa 1000mg / 72-hour infusion matching placebo Cohort2:circa 2000mg / 72-hour infusion matching placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants That Experienced Adverse Events

    Additional Outcome Measures are included in Tables for Serious Adverse Events and Other Adverse Events to report their numbers and frequency.

    Time frame: 87days

Secondary outcomes

  1. Plasma MCI-186 Pharmacokinetics

    The geometric mean values of MCI-186 plasma concentration at the end of the infusion (at 72h) in cohorts 1 and 2 were determined.

    Time frame: 72 hours

  2. mRS, NIHSS, Barthel Index

    Time frame: throughout study

07

Results

Posted May 12, 2014

Participant flow

Participant flow — Overall Study
MilestoneMCI-186 Cohort1MCI-186 Cohort2Placebo Group
Started121311
Completed121311
Not completed000

Outcome measures

PrimaryNumber of Participants That Experienced Adverse Events

Additional Outcome Measures are included in Tables for Serious Adverse Events and Other Adverse Events to report their numbers and frequency.

Time frame:
87days
Reported as:
Number · participants
Number of Participants That Experienced Adverse Events
participantsMCI-186 Cohort1MCI-186 Cohort2Placebo Group
Deaths000
Serious Adverse Events021
Other Adverse Events121010
SecondaryPlasma MCI-186 Pharmacokinetics

The geometric mean values of MCI-186 plasma concentration at the end of the infusion (at 72h) in cohorts 1 and 2 were determined.

Time frame:
72 hours
Reported as:
Geometric mean · ng / ml
Plasma MCI-186 Pharmacokinetics
ng / mlMCI-186 Cohort1MCI-186 Cohort2
Plasma MCI-186 Pharmacokinetics391 ± 24.211595 ± 51.57
SecondarymRS, NIHSS, Barthel Index
Time frame:
throughout study

Results for this outcome have not been posted.

Adverse events

Collected over 87 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MCI-186 Cohort1—0/12 (0%)12/12 (100%)
MCI-186 Cohort2—2/13 (15.4%)10/13 (76.9%)
Placebo Group—1/11 (9.1%)10/11 (90.9%)
Most frequent serious events
Most frequent serious events
EventMCI-186 Cohort1MCI-186 Cohort2Placebo Group
HemiparesisNervous system disorders0/120/131/11
GoutMetabolism and nutrition disorders0/121/130/11
Ischaemic StrokeNervous system disorders0/121/130/11
Most frequent other events
Showing 10 of 63
Most frequent other events
EventMCI-186 Cohort1MCI-186 Cohort2Placebo Group
NauseaGastrointestinal disorders5/121/132/11
HeadacheNervous system disorders4/124/134/11
HypertensionVascular disorders3/122/134/11
ConstipationGastrointestinal disorders1/120/132/11
HypercholesterolaemiaMetabolism and nutrition disorders0/120/132/11
HyperlipidaemiaMetabolism and nutrition disorders2/120/130/11
Atrial FibrillationCardiac disorders0/122/130/11
HyperglycaemiaMetabolism and nutrition disorders0/122/130/11
CataractEye disorders0/120/131/11
Vision BlurredEye disorders0/120/131/11

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MCI-186 Cohort1MCI-186 Cohort2Placebo GroupTotal
<=18 years0000
Between 18 and 65 years59216
>=65 years74920
Sex: Female, Male
Sex: Female, Male(Participants)MCI-186 Cohort1MCI-186 Cohort2Placebo GroupTotal
Female2439
Male109827
08

Study locations

3 sites
  • Helsinki University Central Hospital
    Helsinki, Finland
  • Erasmus Medical Center
    Rotterdam, Netherlands
  • Newcastle upon Tyne Hospitals NHS Foundation Trust
    Newcastle, United Kingdom
09

References and documents

Publications

  • Kaste M, Murayama S, Ford GA, Dippel DW, Walters MR, Tatlisumak T; MCI-186 study group. Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. Cerebrovasc Dis. 2013;36(3):196-204. doi: 10.1159/000353680. Epub 2013 Oct 12. PubMed 24135530 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2009 to primary completion in Nov 2010, 21 months.

Results were first posted in May 2014, 3 years 5 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's 21 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2009
First posted
Jan 14, 2009
StartActual
Feb 28, 2009
Primary completionActual
Nov 30, 2010
CompletionActual
Nov 30, 2010
Results first posted
May 12, 2014
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00821821
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Jan 14, 2009
Start date
Feb 28, 2009
Primary completion
Nov 30, 2010
Completion
Nov 30, 2010
Results posted
May 12, 2014
Last update
Jul 16, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion